These data show that the injection of antigen-loaded EVs can induce immune cell infiltration into tumors, specifically CD8+ T cells, in addition to increased MHC class I expression on tumor cells in the EV-treated groups, which is a requirement for CD8+ T cells to recognize and kill tumor cells. Here, CD8A is linked to neoplasm.